Stereotyped B-cell receptors in chronic lymphocytic leukemia

References

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052–1057.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011;117:1781–1791.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515–1525.
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Belessi C, Hadzidimitriou A, et al. Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood 2005;106:3575–3583.
   PubMed Web of Science ®Google Scholar
• Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200: 519–525.
   PubMed Web of Science ®Google Scholar
• Widhopf GF 2nd, Rassenti LZ, Toy TL, et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004;104:2499–2504.
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104:2879–2885.
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007;109:259–270.
   PubMed Web of Science ®Google Scholar
• Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008;111:1524–1533.
   PubMed Web of Science ®Google Scholar
• Bomben R, Dal Bo M, Capello D, et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol 2009;144:492–506.
   PubMed Web of Science ®Google Scholar
• Darzentas N, Hadzidimitriou A, Murray F, et al. A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia 2010;24:125–132.
   PubMed Web of Science ®Google Scholar
• Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012;119:4467–4475.
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003;101:4952–4957.
   PubMed Web of Science ®Google Scholar
• Ghiotto F, Fais F, Valetto A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004;113:1008–1016.
   PubMed Web of Science ®Google Scholar
• Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005;105: 1678–1685.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Minga E, Hadzidimitriou A, et al. BcR stereotypy makes a clinical difference in CLL: relevations from a multi-institutional series of 4615 cases. Presented at 17th EHA meeting, 14–17 June 2012, Amsterdam, The Netherlands.
   Google Scholar
• Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006;107:2889–2894.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Wakai M, Silver J, et al. Biased usage of variable and constant-region Ig genes by IgG+, CD5 + human leukemic B cells. Ann NY Acad Sci 1992;651:477–479.
   PubMed Web of Science ®Google Scholar
• Athanasiadou A, Stamatopoulos K, Gaitatzi M, et al. Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins. Haematologica 2008;93:473–474.
   PubMed Web of Science ®Google Scholar
• Marincevic M, Cahill N, Gunnarsson R, et al. High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with “stereotyped” IGHV3-21 and IGHV4-34 B-cell receptors. Haematologica 2010;95:1519–1525.
   PubMed Web of Science ®Google Scholar
• Schweighofer CD, Huh YO, Luthra R, et al. The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. Int J Cancer 2011;128:2759–2764.
   PubMed Web of Science ®Google Scholar
• Strefford JC, Sutton LA, Baliakas P, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 2013;27:2196–2199.
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood 2013;121:4902–4905.
   PubMed Web of Science ®Google Scholar
• Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300:455.
   PubMed Web of Science ®Google Scholar
• Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012;44:1236–1242.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37–50.
   PubMed Web of Science ®Google Scholar
• Kanduri M, Cahill N, Goransson H, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 2010;115:296–305.
   PubMed Web of Science ®Google Scholar
• Kanduri M, Marincevic M, Halldorsdottir AM, et al. Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. Epigenetics 2012;7:1435–1442.
   PubMed Web of Science ®Google Scholar
• Marincevic M, Mansouri M, Kanduri M, et al. Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Haematologica 2010;95:2072–2079.
   PubMed Web of Science ®Google Scholar
• Mansouri L, Gunnarsson R, Sutton LA, et al. Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia. Am J Hematol 2012;87:737–740.
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Chiaretti S, Santangelo S, et al. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between BCR structure, function and patients’ prognosis. Am J Hematol 2014;89:74–82.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011;12:99–110.
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10:111–122.
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011;11:163–175.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 2010;1799:694–701.
   PubMed Web of Science ®Google Scholar
• Valeri N, Vannini I, Fanini F, et al. Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome 2009;20:573–580.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524–15529.
   PubMed Web of Science ®Google Scholar
• Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793–1801.
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009;113:5237–5245.
   PubMed Web of Science ®Google Scholar
• Rossi S, Shimizu M, Barbarotto E, et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010;116: 945–952.
   PubMed Web of Science ®Google Scholar
• Ferracin M, Zagatti B, Rizzotto L, et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer 2010;9:123.
   PubMed Web of Science ®Google Scholar
• Moussay E, Palissot V, Vallar L, et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer 2010;9:115.
   PubMed Web of Science ®Google Scholar
• Pallasch CP, Patz M, Park YJ, et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 2009;114:3255–3264.
   PubMed Web of Science ®Google Scholar
• Frenquelli M, Muzio M, Scielzo C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010; 115:3949–3959.
   PubMed Web of Science ®Google Scholar
• Wang M, Tan LP, Dijkstra MK, et al. miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 2008;215:13–20.
   PubMed Web of Science ®Google Scholar
• Papakonstantinou N, Ntoufa S, Chartomatsidou E, et al. Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol Med 2013;19:115–123.
   PubMed Web of Science ®Google Scholar
• Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695–1699.
   PubMed Web of Science ®Google Scholar
• Cao P, Deng Z, Wan M, et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 2010;9:108.
   PubMed Web of Science ®Google Scholar
• Binder M, Muller F, Jackst A, et al. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 2011;117:1891–1900.
   PubMed Web of Science ®Google Scholar
• Broker BM, Klajman A, Youinou P, et al. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1988;1:469–481.
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Wakai M, Tse DB, et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 1989;169:255–268.
   PubMed Web of Science ®Google Scholar
• Herve M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005; 115:1636–1643.
   PubMed Web of Science ®Google Scholar
• Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008;111:3838–3848.
   PubMed Web of Science ®Google Scholar
• Chu CC, Catera R, Hatzi K, et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008;112:5122–5129.
   PubMed Web of Science ®Google Scholar
• Conti MA, Adelstein RS. Nonmuscle myosin II moves in new directions. J Cell Sci 2008;121:11–18.
   PubMed Web of Science ®Google Scholar
• Chu CC, Catera R, Zhang L, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010;115:3907–3915.
   PubMed Web of Science ®Google Scholar
• Kostareli E, Hadzidimitriou A, Stavroyianni N, et al. Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Leukemia 2009;23:919–924.
   PubMed Web of Science ®Google Scholar
• Kostareli E, Gounari M, Janus A, et al. Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia 2012;26: 1127–1131.
   PubMed Web of Science ®Google Scholar
• Gounari M, Ntoufa S, Chu C, et al. Promiscuous antigen reactivity may underlie clinical aggressiveness and increased risk for Richter's syndrome in chronic lymphocytic leukemia with stereotyped IGHV4-39/IGKV1(D)-39 B cell receptors. Blood 2012;120(Suppl. 1): Abstract 561.
   Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675–680.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005;17:338–344.
   PubMed Web of Science ®Google Scholar
• Meyer-Bahlburg A, Khim S, Rawlings DJ. B cell intrinsic TLR signals amplify but are not required for humoral immunity. J Exp Med 2007;204:3095–3101.
   PubMed Web of Science ®Google Scholar
• Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006;36:810–816.
   PubMed Web of Science ®Google Scholar
• Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005;202:1171–1177.
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Wooldridge JE, Blackwell SE, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005;77:378–387.
   PubMed Web of Science ®Google Scholar
• Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999–1006.
   PubMed Web of Science ®Google Scholar
• Spaner DE, Shi Y, White D, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006;20:286–295.
   PubMed Web of Science ®Google Scholar
• Shi Y, White D, He L, et al. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007;67:1823–1831.
   PubMed Web of Science ®Google Scholar
• Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 2011;96:1644–1652.
   PubMed Web of Science ®Google Scholar
• Ntoufa S, Vardi A, Papakonstantinou N, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med 2012;18:1281–1291.
   PubMed Web of Science ®Google Scholar
• Oscier D. Do we need novel prognostic markers? Presented at 18th EHA meeting, 13–16 June 2013, Stockholm, Sweden.
   Google Scholar
• Stamatopoulos KGP, Rosenquist R. New biological prognostic markers in CLL. Milan, Italy: Wolters Kluwer; 2010.
   Google Scholar
• Rosenquist R, Cortese D, Bhoi S, et al. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?Leuk Lymphoma 2013;54:2351–2364.
   PubMed Web of Science ®Google Scholar
• Lanham S, Hamblin T, Oscier D, et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003;101: 1087–1093.
   PubMed Web of Science ®Google Scholar
• Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008;112:188–195.
   PubMed Web of Science ®Google Scholar
• Hivroz C, Geny B, Brouet JC, et al. Altered signal transduction secondary to surface IgM cross-linking on B-chronic lymphocytic leukemia cells. Differential activation of the phosphatidylinositol-specific phospholipase C. J Immunol 1990;144:2351–2358.
   Google Scholar
• Semichon M, Merle-Beral H, Lang V, et al. Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia 1997;11:1921–1928.
   PubMed Web of Science ®Google Scholar
• PI3K-delta inhibitor produces long-lasting responses. Cancer Discov 2013;3:OF11.
   Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 2009;15: 4415–4422.
   PubMed Web of Science ®Google Scholar
• Maura F, Visco C, Falisi E, et al. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol 2013;88:32–36.
   PubMed Web of Science ®Google Scholar
• Visco C, Maura F, Tuana G, et al. Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors. Clin Cancer Res 2012;18:1870–1878.
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262–2264.
   PubMed Web of Science ®Google Scholar
• Cunningham AF, Gaspal F, Serre K, et al. Salmonella induces a switched antibody response without germinal centers that impedes the extracellular spread of infection. J Immunol 2007;178: 6200–6207.
   PubMed Web of Science ®Google Scholar
• Rothaeusler K, Baumgarth N. B-cell fate decisions following influenza virus infection. Eur J Immunol 2010;40:366–377.
   PubMed Web of Science ®Google Scholar
• Chappell CP, Draves KE, Giltiay NV, et al. Extrafollicular B cell activation by marginal zone dendritic cells drives T cell-dependent antibody responses. J Exp Med 2012;209:1825–1840.
   PubMed Web of Science ®Google Scholar
• Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol 2005;26:347–362.
   PubMed Web of Science ®Google Scholar
• Montecino-Rodriguez E, Dorshkind K. B-1 B cell development in the fetus and adult. Immunity 2012;36:13–21.
   PubMed Web of Science ®Google Scholar
• Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20 + CD27+ CD43 + CD70. J Exp Med 2011;208: 67–80.
   PubMed Web of Science ®Google Scholar
• Kaji T, Ishige A, Hikida M, et al. Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory. J Exp Med 2012;209:2079–2097.
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Pape KA, Jenkins MK. A germinal center-independent pathway generates unswitched memory B cells early in the primary response. J Exp Med 2012;209:597–606.
   PubMed Web of Science ®Google Scholar
• Potter KN, Mockridge CI, Neville L, et al. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clin Cancer Res 2006;12:1672–1679.
   PubMed Web of Science ®Google Scholar
• Vardi A, Agathangelidis A, Sutton LA, et al. IgG-switched CLL has a distinct immunogenetic signature from the common MD variant: ontogenetic implications. Clin Cancer Res 2014;20:323–330.
   PubMed Web of Science ®Google Scholar
• Bhat NM, Bieber MM, Spellerberg MB, et al. Recognition of auto- and exoantigens by V4-34 gene encoded antibodies. Scand J Immunol 2000;51:134–140.
   PubMed Web of Science ®Google Scholar
• Richardson C, Chida AS, Adlowitz D, et al. Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus. J Immunol 2013;191:4926–4939.
   PubMed Web of Science ®Google Scholar
• Hadzidimitriou A, Darzentas N, Murray F, et al. Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia. Blood 2009;113: 403–411.
   PubMed Web of Science ®Google Scholar
• Catera R, Magli A, Kolitz J, et al. Somatic hypermutation in stereotyped subset 4 BcRs/mAbs of CLL patients, expressing IGHV4-34 gene, edits anti-DNA reactivity. Blood 2011;118(Suppl. 1): Abstract 2444.
   Google Scholar